TY - JOUR
T1 - Prevalence of prothrombotic polymorphisms in a selected cohort of cryptogenic and noncryptogenic ischemic stroke patients
AU - Calabrò, Rocco Salvatore
AU - La Spina, Paolino
AU - Serra, Salvatore
AU - Laganà, Angelina
AU - Postorino, Paolo
AU - Savica, Rodolfo
AU - Mammì, Corrado
AU - Laganà, Carmelo
AU - Musolino, Rosa
PY - 2009/12/1
Y1 - 2009/12/1
N2 - Ischemic stroke is a complex multifactorial disease and approximately 30%, especially in the young, are cryptogenic. In some of the patients with cryptogenic ischemic stroke the underlying risk factor may be a prothrombotic state. We studied 101 patients with ischemic stroke under 55 years of age. All the patients underwent an extensive diagnostic evaluation to determine the cause of stroke. Common variations in the genes encoding factor V, prothrombin, 5,10-methylenetetrahydrofolate reductase, plasminogen activator inhibitor-1, and human platelet alloantigens-1 were evaluated. Of the 101 patients with ischemic stroke, 28 patients had cryptogenic ischemic stroke. At least one of the different genetic polymorphisms investigated was present in 44% patients in the total group and in 48% of patients with cryptogenic ischemic stroke. In this study population under 55 years of age there was no significant difference in the prevalence of various genetic polymorphisms, factor V, prothrombin, 5,10-methylenetetrahydrofolate reductase, plasminogen activator inhibitor-1, and human platelet alloantigens) in patients with cryptogenic ischemic stroke and in patients with ischemic stroke of determined cause.
AB - Ischemic stroke is a complex multifactorial disease and approximately 30%, especially in the young, are cryptogenic. In some of the patients with cryptogenic ischemic stroke the underlying risk factor may be a prothrombotic state. We studied 101 patients with ischemic stroke under 55 years of age. All the patients underwent an extensive diagnostic evaluation to determine the cause of stroke. Common variations in the genes encoding factor V, prothrombin, 5,10-methylenetetrahydrofolate reductase, plasminogen activator inhibitor-1, and human platelet alloantigens-1 were evaluated. Of the 101 patients with ischemic stroke, 28 patients had cryptogenic ischemic stroke. At least one of the different genetic polymorphisms investigated was present in 44% patients in the total group and in 48% of patients with cryptogenic ischemic stroke. In this study population under 55 years of age there was no significant difference in the prevalence of various genetic polymorphisms, factor V, prothrombin, 5,10-methylenetetrahydrofolate reductase, plasminogen activator inhibitor-1, and human platelet alloantigens) in patients with cryptogenic ischemic stroke and in patients with ischemic stroke of determined cause.
KW - Cryptogenic stroke
KW - Juvenile ischemic stroke
KW - Prothrombotic genetic polymorphisms
UR - http://www.scopus.com/inward/record.url?scp=72849153424&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=72849153424&partnerID=8YFLogxK
U2 - 10.4103/0028-3886.57819
DO - 10.4103/0028-3886.57819
M3 - Article
C2 - 19934566
AN - SCOPUS:72849153424
SN - 0028-3886
VL - 57
SP - 636
EP - 637
JO - Neurology India
JF - Neurology India
IS - 5
ER -